Rodrigo Cristofoletti
Overview
Explore the profile of Rodrigo Cristofoletti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
349
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudolph N, Charbe N, Plano D, Shoyaib A, Pal A, Boyce H, et al.
Eur J Pharm Sci
. 2025 Feb;
:107047.
PMID: 39983931
This study leverages physiologically based biopharmaceutics modeling (PBBM) to predict the clinical performance of two itraconazole (ITRA) amorphous solid dispersions (ASDs), Sempera® and Tolsura®, under fasted and fed state conditions,...
2.
Chen H, Chun D, Lingineni K, Guzy S, Cristofoletti R, Hoechel J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Nov;
13(11):2016-2025.
PMID: 39551952
Breakthrough bleeding (BTB) is a common side effect of hormonal contraception and is thought to impact adherence to combined oral contraceptives (COCs) but respective dose-response relationships are not yet fully...
3.
Beran K, Abrahamsson B, Charoo N, Cristofoletti R, Holm R, Kambayashi A, et al.
J Pharm Sci
. 2024 Nov;
114(2):660-680.
PMID: 39547650
According to the ICH M9 Guideline, the triazole antifungal voriconazole is a Biopharmaceutics Classification System (BCS) class II drug, being highly soluble at the highest dose strength but not at...
4.
Beran K, Abrahamsson B, Charoo N, Cristofoletti R, Holm R, Kambayashi A, et al.
J Pharm Sci
. 2024 Oct;
114(2):644-659.
PMID: 39454947
Lemborexant is a dual orexin receptor antagonist assigned to class II of the Biopharmaceutics Classification System (BCS). Thus, the ICH M9 Guideline excludes immediate-release (IR) solid oral dosage forms containing...
5.
Desai D, Schmidt S, Cristofoletti R
Front Pharmacol
. 2024 Oct;
15:1454785.
PMID: 39372210
In-vivo CRISPR Cas genome editing is a complex therapy involving lipid nanoparticle (LNP), messenger RNA (mRNA), and single guide RNA (sgRNA). This novel modality requires prior modeling to predict dose-exposure-response...
6.
Kambayashi A, Iida M, Ishihara M, Takahashi Y, Abrahamsson B, Charoo N, et al.
J Pharm Sci
. 2024 Aug;
113(11):3137-3144.
PMID: 39154736
The present monograph discusses the possibility of BCS-based biowaivers for immediate release pharmaceutical products containing raltegravir potassium, which is used to treat human immunodeficiency virus (HIV) infections. Raltegravir potassium can...
7.
Pepin X, Arora S, Borges L, Cano-Vega M, Carducci T, Chatterjee P, et al.
Mol Pharm
. 2024 Jul;
21(8):3697-3731.
PMID: 38946085
This Article shares the proceedings from the August 29th, 2023 (day 1) workshop "Physiologically Based Biopharmaceutics Modeling (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives". The focus...
8.
Yin X, Cicali B, Rodriguez-Vera L, Lukacova V, Cristofoletti R, Schmidt S
Pharmaceutics
. 2024 Jun;
16(6).
PMID: 38931859
Carbamazepine (CBZ) is commonly prescribed for epilepsy and frequently used in polypharmacy. However, concerns arise regarding its ability to induce the metabolism of other drugs, including itself, potentially leading to...
9.
Pippa L, Vozmediano V, Mitrov-Winkelmolen L, Touw D, Soliman A, Cristofoletti R, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Jun;
13(9):1528-1541.
PMID: 38923321
This study employed physiologically-based pharmacokinetic-pharmacodynamics (PBPK/PD) modeling to predict the effect of obesity and gastric bypass surgery on the pharmacokinetics and intragastric pH following omeprazole treatment. The simulated plasma concentrations...
10.
Charoo N, Selvasudha N, Kath Z, Abrahamsson B, Cristofoletti R, Kambayashi A, et al.
J Pharm Sci
. 2024 Jun;
113(9):2981-2993.
PMID: 38857646
In this monograph, the potential use of methods based on the Biopharmaceutics Classification System (BCS) framework to evaluate the bioequivalence of solid immediate-release (IR) oral dosage forms containing fexofenadine hydrochloride...